Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Rudén U[au]:

Search results

Items: 1 to 50 of 60

1.

More than 20 years of research into the quality of life of people with HIV and AIDS--a descriptive review of study characteristics and methodological approaches of published empirical studies.

Drewes J, Gusy B, Rüden Uv.

J Int Assoc Provid AIDS Care. 2013 Jan-Feb;12(1):18-22. doi: 10.1177/1545109712456429. Epub 2012 Oct 4. Review.

PMID:
23042792
2.

Minimal change in HSV-2 seroreactivity: a cross-sectional Swedish population study.

Jonsson MK, Levi M, Rudén U, Wahren B.

Scand J Infect Dis. 2006;38(5):357-65.

PMID:
16709538
3.

Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.

Parment PA, Svahn A, Rudén U, Bråkenhielm G, Storsaeter J, Akesson L, Linde A.

Scand J Infect Dis. 2003;35(10):736-42.

PMID:
14606613
4.

Immunogenic regions of the GA733-2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma.

Mosolits S, Steinitz M, Harmenberg U, Ruden U, Eriksson E, Mellstedt H, Fagerberg J.

Cancer Immunol Immunother. 2002 Jun;51(4):209-18. Epub 2002 Apr 10.

PMID:
12012108
5.

Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia.

Rezvany MR, Jeddi-Tehrani M, Rabbani H, Rudén U, Hammarström L, Osterborg A, Wigzell H, Mellstedt H.

Br J Haematol. 2000 Oct;111(1):230-8.

PMID:
11091206
6.

The European Sero-Epidemiology Network: standardizing the enzyme immunoassay results for measles, mumps and rubella.

Andrews N, Pebody RG, Berbers G, Blondeau C, Crovari P, Davidkin I, Farrington P, Fievet-Groyne F, Gabutti G, Gerike E, Giordano C, Hesketh L, Marzec T, Morgan-Capner P, Osborne K, Pleisner AM, Raux M, Tischer A, Ruden U, Valle M, Miller E.

Epidemiol Infect. 2000 Aug;125(1):127-41.

7.

Seroprevalence of viral childhood infections in Eritrea.

Tolfvenstam T, Enbom M, Ghebrekidan H, Rudén U, Linde A, Grandien M, Wahren B.

J Clin Virol. 2000 Feb;16(1):49-54.

PMID:
10680740
8.

Seroprevalence of human herpes virus 8 in different Eritrean population groups.

Enbom M, Tolfvenstam T, Ghebrekidan H, Rudén U, Grandien M, Wahren B, Linde A.

J Clin Virol. 1999 Dec;14(3):167-72.

PMID:
10614853
9.

Humoral and cell-mediated immune responses in humans to the NSP4 enterotoxin of rotavirus.

Johansen K, Hinkula J, Espinoza F, Levi M, Zeng C, Rudén U, Vesikari T, Estes M, Svensson L.

J Med Virol. 1999 Nov;59(3):369-77.

PMID:
10502271
10.

The use of peptides from glycoproteins G-2 and D-1 for detecting herpes simplex virus type 2 and type-common antibodies.

Levi M, Rudén U, Carlberg H, Wahren B.

J Clin Virol. 1999 May;12(3):243-52.

PMID:
10382821
11.

Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma.

Mosolits S, Harmenberg U, Rudén U, Ohman L, Nilsson B, Wahren B, Fagerberg J, Mellstedt H.

Cancer Immunol Immunother. 1999 Feb;47(6):315-20.

PMID:
10203061
12.

Prevalence of herpes simplex virus types 1 and 2, cytomegalovirus, and varicella-zoster virus infections in Eritrea.

Ghebrekidan H, Rudén U, Cox S, Wahren B, Grandien M.

J Clin Virol. 1999 Jan;12(1):53-64.

PMID:
10073414
13.

T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma.

Fagerberg J, Yi Q, Gigliotti D, Harmenberg U, Rudén U, Persson B, Osterborg A, Mellstedt H.

Int J Cancer. 1999 Mar 1;80(5):671-80.

14.
15.

Immunoglobulin G abnormalities in HIV-1 infected individuals with lymphoma.

Lundholm P, Lucht E, Svedmyr E, Rudén U, Linde A, Wahren B.

Immunotechnology. 1998 Jun;4(1):29-36.

PMID:
9661812
16.

Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.

Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, Rudén U, Lefvert AK, Holm G, Mellstedt H.

Blood. 1998 Apr 1;91(7):2459-66.

17.

Induction of a T- and B-cell response against a unique amino acid sequence of the mouse IgG2A hinge region in a MAb-treated patient.

Wersäll P, Fagerberg J, Ohlsson I, Rudén U, Boethius J, Mellstedt H.

Int J Cancer. 1997 Dec 10;73(6):790-4.

18.

HIV-1 epitopes exposed by hybrid hepatitis B core particles affect proliferation of peripheral blood mononuclear cells from HIV-1 positive donors.

Isaguliants MG, Nordlund S, Sällberg M, Smirnov VD, Rudén U, Wahren B.

Immunol Lett. 1996 Aug;52(1):37-44. Erratum in: Immunol Lett 1997 Jan;55(1):61.

PMID:
8877417
19.
20.

[Composition of HIV-1 B-epitopes and heterologous T-cell epitopes. I. Maintenance of antigenic properties of HIV-1 B-epitopes].

Isaguliants MG, Koshida R, Ruden U, Varen B.

Biokhimiia. 1996 Jul;61(7):1221-9. Russian.

PMID:
9035735
21.
22.

Evaluation of serological assays for identification of parvovirus B19 immunoglobulin M.

Tolfvenstam T, Rudén U, Broliden K.

Clin Diagn Lab Immunol. 1996 Mar;3(2):147-50.

23.

Immune responses to the HIV rev regulatory gene.

Wahren B, Brytting MM, Engström G, Hinkula J, Levi M, Ståhle EL, Ohlsson S, Rudén U, Schwartz S.

Antibiot Chemother (1971). 1996;48:105-12. No abstract available.

PMID:
8726512
24.

Immunogenic combinations of HIV-1 B- and heterologous T-cell epitopes.

Isaguliants M, Rudén U, Gilljam G, Wahren B.

Immunol Lett. 1994 Oct;42(3):173-8.

PMID:
7534271
25.

Identification of hepatitis B virus core protein regions exposed or internalized at the surface of HBcAg particles by scanning with monoclonal antibodies.

Pushko P, Sallberg M, Borisova G, Ruden U, Bichko V, Wahren B, Pumpens P, Magnius L.

Virology. 1994 Aug 1;202(2):912-20.

PMID:
8030252
26.

Linear epitopes of HIV-1, presented as hybrids with Escherichia coli beta-galactosidase or synthetic peptides.

Isaguliants MG, Sukhanova LL, Levi M, Bobkov AP, Kalinina TI, Rudén U, Smirnov VD, Wahren B.

AIDS Res Hum Retroviruses. 1994 Jun;10(6):655-64.

PMID:
7521191
27.

Locations of antibody binding sites within conserved regions of the hepatitis C virus core protein.

Sällberg M, Pumpen P, Zhang ZX, Lundholm P, Gusars I, Rudén U, Wahren B, Magnius LO.

J Med Virol. 1994 May;43(1):62-8.

PMID:
7521899
28.
29.

Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.

Levi M, Rudén U, Birx D, Loomis L, Redfield R, Lövgren K, Akerblom L, Sandström E, Wahren B.

J Acquir Immune Defic Syndr. 1993 Aug;6(8):855-64.

PMID:
8315572
30.

A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro.

Levi M, Sällberg M, Rudén U, Herlyn D, Maruyama H, Wigzell H, Marks J, Wahren B.

Proc Natl Acad Sci U S A. 1993 May 15;90(10):4374-8.

32.

Immunodominant regions within the hepatitis C virus core and putative matrix proteins.

Sällberg M, Rudén U, Wahren B, Magnius LO.

J Clin Microbiol. 1992 Aug;30(8):1989-94.

33.
34.

Identification of antigenic regions of the human Ro 60 kDa protein using recombinant antigen and synthetic peptides.

Wahren M, Rudén U, Andersson B, Ringertz NR, Pettersson I.

J Autoimmun. 1992 Jun;5(3):319-32.

PMID:
1382431
35.

Identification of B-cell antigenic sites on HIV-2 gp125.

Mannervik M, Putkonen P, Rudén U, Kent KA, Norrby E, Wahren B, Broliden PA.

J Acquir Immune Defic Syndr. 1992;5(2):177-87.

PMID:
1370692
36.

Characterization of a major antigenic region on gp55 of human cytomegalovirus.

Silvestri M, Sundqvist VA, Rudén U, Wahren B.

J Gen Virol. 1991 Dec;72 ( Pt 12):3017-23.

PMID:
1662693
37.
38.

Immunological characterization of the human immunodeficiency virus type 1 reverse transcriptase protein by the use of monoclonal antibodies.

Orvell C, Unge T, Bhikhabhai R, Bäckbro K, Rudén U, Strandberg B, Wahren B, Fenyö EM.

J Gen Virol. 1991 Aug;72 ( Pt 8):1913-8.

PMID:
1714942
39.

Human and murine B-cells recognize the HBeAg/beta (or HBe2) epitope as a linear determinant.

Sällberg M, Rudén U, Wahren B, Noah M, Magnius LO.

Mol Immunol. 1991 Jul;28(7):719-26.

PMID:
1713295
40.

Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus.

Ohlin M, Sundqvist VA, Gilljam G, Rudén U, Gombert FO, Wahren B, Borrebaeck CA.

Clin Exp Immunol. 1991 Jun;84(3):508-14.

41.

Characterisation of a linear binding site for a monoclonal antibody to hepatitis B core antigen.

Sällberg M, Rudén U, Magnius LO, Harthus HP, Noah M, Wahren B.

J Med Virol. 1991 Apr;33(4):248-52.

PMID:
1713264
42.

Search for epitopic sites of antibodies to germ cell alkaline phosphatase.

Harmenberg U, Ljungdahl-Ståhle E, Rudén U, Wahren B.

Cancer Commun. 1991;3(10-11):305-11.

PMID:
1722106
43.

Specific synthetic peptides for detection of and discrimination between HIV-1 and HIV-2 infection.

Broliden PA, Rudén U, Ouattara AS, de Thé G, Sølver E, Trojnar J, Wahren B.

J Acquir Immune Defic Syndr. 1991;4(10):952-8.

PMID:
1679844
44.

Serum levels and catabolism of 3'-azido-3'-deoxythymidine in vivo measured using a specific radioimmunoassay.

Cox S, Rudén U, Nagy K, Albert J, Holmberg V, Sandström E, Wahren B.

J Virol Methods. 1990 Oct;30(1):89-98.

PMID:
2086597
45.

Profiles of epitope-defined markers in sera from patients with testicular germ cell tumors.

Yamamoto H, Rudén U, Esposti P, Hirano K, Stigbrand T, Andersson L, Hisazumi H, Wahren B.

Urol Res. 1988;16(1):31-6.

PMID:
2449757
46.

Patterns of seminoma tissue markers and deletions.

Yamamoto H, Rudén U, Ljungdahl-Ståhle E, Brehmer-Andersson E, Hirano K, Hisazumi H, Stigbrand T, Wahren B.

Int J Cancer. 1987 Nov 15;40(5):615-9.

PMID:
2445700
47.

Acyclic guanosine analogs as inhibitors of human cytomegalovirus.

Wahren B, Larsson A, Rudén U, Sundqvist A, Sølver E.

Antimicrob Agents Chemother. 1987 Feb;31(2):317-20.

48.

Improved radioimmunolocalization of carcinomas using Fab fragments with anti-CEA specificity.

Ljungdahl-Ståhle E, Harmenberg U, Rudén U, Hammarström S, Stigbrand T, Wahren B.

Tumour Biol. 1986;7(5-6):353-60.

PMID:
3576081
49.

Polyclonal and monoclonal anti-CEA antibodies in immunolocalization of colorectal cancer.

Wahren B, Hammarström S, Harmenberg U, von Krusenstierna S, Larsson SA, Lundell G, Rudén U, Schnell PO.

Tumour Biol. 1986;7(5-6):361-9.

PMID:
3495029
50.

Activity of the cytomegalovirus genome in the presence of PPi analogs.

Wahren B, Rudén U, Gadler H, Oberg B, Eriksson B.

J Virol. 1985 Dec;56(3):996-1001.

Supplemental Content

Support Center